On September 28, 2016 Mirna Therapeutics, Inc. (the "Company") reported that it received verbal notice from the U.S. Food and Drug Administration (the "FDA") that the Company’s Investigational New Drug ("IND") for MRX34, its investigational microRNA therapy for multiple cancers, has been placed on full clinical hold ((Press release, Mirna Therapeutics, SEP 28, 2016, View Source [SID1234515521]). The Company anticipates that it will receive a formal clinical hold letter from the FDA within 30 days. This follows the Company’s announcement on September 20, 2016 that it was voluntarily stopping its Phase 1 trial for MRX34

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!